Eye CancerLast Updated: September 02, 2008 This section has been reviewed and approved by the Cancer.Net Editorial Board, 08/08 Overview
Eye cancer is a general term used to describe many types of tumors that occur in various parts of the eye. It occurs when cells in or around the eye grow abnormally and form a tumor. A tumor may be benign (noncancerous) or malignant (cancerous, meaning cells can spread to other parts of the body). Cancer that forms in the eyeball is called an intraocular malignancy. Parts of the eye The eye is the organ that collects light and sends messages to the brain to form a picture. The three main parts of the eye are:
The outer part of the eye is made up of the sclera, retina, and uvea. The sclera is the outer wall of the eyeball. The retina is a thin-layered structure that lines the eyeball and sends information from the eye to the brain. The uvea nourishes the eye. Both the retina and the uvea contain blood vessels. The uvea consists of the following:
Types of intraocular cancer The most common intraocular cancer in adults is uveal metastases, which is cancer that has spread to uvea from another place in the body, called secondary cancer. This article is about primary intraocular cancer, meaning that the tumor started in the eye, not somewhere else in the body. Melanoma is the most common type of primary intraocular cancer in adults. It begins when pigmented (colored) cells in the eye called melanocytes grow uncontrollably. Intraocular melanoma is also called uveal melanoma. Medical doctors who specialize in the diseases and function of the eye are called ophthalmologists (or “eye MDs”). These doctors can diagnose and treat intraocular melanoma. Optometrists are another type of eye doctor. They prescribe eyeglasses and contact lenses. They are not medical doctors and are not trained to treat intraocular cancer. Other, less common types of an intraocular tumor include: Intraocular lymphoma is lymphoma that begins in the eyeball. This condition is rare and can be difficult for doctors to diagnose. Many doctors consider intraocular lymphoma to be a type of central nervous system lymphoma. Most intraocular lymphomas are non-Hodgkin lymphoma. Refer to the Cancer.Net Guide to Non-Hodgkin Lymphoma for more information. Retinoblastoma is a rare form of childhood eye cancer. Information about this cancer can be found in the Cancer.Net Guide to Retinoblastoma, Childhood Cancer. Hemangioma is a benign vascular tumor of the choroid and retina. In addition, rare tumors of the eye include: Conjunctival melanoma, a tumor of the conjunctiva (a membrane that lines the eyelid and eyeball). If this tumor is not treated, it can spread to the lymph nodes. This tumor tends to recur (come back after treatment) on the eye’s surface and looks like dark spots on the eye. Doctors often perform a biopsy (removal of a sample of the tissue for examination under a microscope) on a lesion that appears to be conjunctival melanoma. Eyelid carcinoma (basal or squamous cell) is a variation of skin cancer. This tumor may be surgically removed and is usually not dangerous if it is treated early. Refer to the Cancer.Net Guide to Eyelid Cancer for more information. Statistics In 2009, an estimated 2,350 adults (1,200 men and 1,150 women) in the United States will be diagnosed with primary intraocular cancer. It is estimated that 230 deaths (120 men and 110 women) from this disease will occur this year. Most new cases (between 1,300 and 1,800) of primary intraocular cancer this year will be melanomas. While the number of new cases and deaths from skin melanoma has been increasing over the past 30 years, the number of new intraocular melanoma cases has remained constant or even slightly decreased during this time. Cancer that has spread to the eye from another place in the body (secondary eye cancer) is more common than primary eye cancer. The five-year relative survival rate (the percentage of people who survive at least five years after the cancer is detected, excluding those who die from other disease) depends on the size and location of the tumor. Iris melanoma is rare and does not usually spread. The five-year relative survival rate for people with iris melanoma is about 95%. Choroidal melanoma is the most common type of intraocular melanoma.
Ciliary body melanoma is rare. Five-year relative survival rates are hard to determine for this type of melanoma, although it generally has a poorer prognosis (chance of recovery) than choroidal melanoma because it is typically diagnosed at a more advanced stage. Cancer survival statistics should be interpreted with caution. These estimates are based on data from thousands of cases of this type of cancer in the United States each year, but the actual risk for a particular individual may differ. It is not possible to tell a person how long he or she will live with eye cancer. Because the survival statistics are measured in five-year (or sometimes one-year) intervals, they may not represent advances made in the treatment or diagnosis of this cancer. Statistics adapted from the American Cancer Society's publication, Cancer Facts & Figures 2009, and the National Cancer Institute. Find out more about basic cancer terms used in this section. Medical Illustrations
Risk Factors
A risk factor is anything that increases a person’s chance of developing cancer. Some risk factors can be controlled, such as smoking, and some cannot be controlled, such as age and family history. Although risk factors can influence the development of cancer, most do not directly cause cancer. Some people with several risk factors never develop the disease, while others with no known risk factors do. However, knowing your risk factors and communicating them to your doctor may help you make more informed lifestyle and health-care choices. The following factors can raise a person’s risk of developing eye cancer: Age. Most cases of primary intraocular melanoma occur in people over the age of 50, and the average age of diagnosis is 55. It is rare in children and people over the age of 70. Race. Primary intraocular melanoma is more common in white people and less common in black people. Gender. Intraocular melanoma affects about equal numbers of men and women. Individual history. People with the following medical conditions have a higher risk of developing primary intraocular melanoma:
Family history. Intraocular melanoma doesn’t generally run in families, although a couple of rare cases have been reported. Other. Some studies have suggested that sunlight or certain chemicals may be a risk factor for intraocular melanoma, but the data are not conclusive about this association. It is recommended that people with a combination of these risk factors see an ophthalmologist for a yearly examination and protect their eyes from ultraviolet (UV) radiation with sunglasses. Anyone who finds unusual moles or other skin growths around the eye or elsewhere on the body should see a dermatologist (a doctor specializing in skin diseases), especially if there is a family history of melanoma. Symptoms
People with intraocular melanoma often have no symptoms. Many times, an ophthalmologist finds the melanoma during a routine eye examination. The most common symptom is painless loss of vision. Unlike choroidal and ciliary body melanoma, iris melanoma can sometimes be seen because it looks like dark spots on the eye. People with eye cancer may experience the following symptoms. Sometimes people with eye cancer do not show any of these symptoms. Or, these symptoms may be caused by a medical condition that is not cancer. If you are concerned about a symptom on this list, please talk with your doctor.
Diagnosis
Doctors use many tests to diagnose cancer and determine if it has metastasized (spread). Some tests may also determine which treatments may be the most effective. For most types of cancer, a biopsy is the only way to make a definitive diagnosis of cancer. However, for eye melanoma, a diagnosis can often be made without a biopsy. The doctor may also suggest other tests that will help make a diagnosis. Imaging tests may be used to find out whether the cancer has metastasized. Your doctor may consider these factors when choosing a diagnostic test:
In addition to a physical examination, the following tests may be used to diagnose eye cancer: Eye examination. Most cases of melanoma are found during a regular eye examination. The doctor will examine the eye with a lighted instrument called an ophthalmoscope and a slit lamp (a microscope with a light attached to it). Ultrasound. An ultrasound uses sound waves to create a picture of the eye. Fluorescein angiography. This procedure takes a picture of the blood vessels in the eye. A fluorescent dye (called fluorescein) is injected into the patient’s arm. The dye moves through the body and into the blood vessels in the back of the eye. The doctor then takes several, quick pictures of the eye. Fluorescein angiography may be used to rule out eye problems other than cancer. Indocyanine green angiography is a similar test that uses a different dye, called indocyanine green. Fine needle biopsy. This procedure removes tumor cells from the eye with a needle. This allows the doctor to look at the cells under a microscope. Because doctors can correctly diagnose more than 95% of intraocular melanoma without a biopsy, this procedure is not needed for most people. Tests for metastases. A tumor that starts in the eye can spread through the blood to other parts of the body, most commonly the liver. The doctor may see if the tumor has spread to the liver by testing the levels of liver enzymes in the person’s blood or through a computed tomography (CT or CAT) scan or an ultrasound of the liver. A CT scan creates a three-dimensional picture of the inside of the body with an x-ray machine. A computer then combines these images into a detailed, cross-sectional view that shows any abnormalities or tumors. Sometimes, a contrast medium (special dye) is injected into a patient’s vein to provide better detail. The doctor may also order a positron emission tomography (PET scan). A PET scan is a way to create pictures of organs and tissues inside the body. A small amount of radioactive substance is injected into a patient’s body and absorbed by the organs or tissues being studied. This substance gives off energy that is detected by a scanner, which produces the images. The doctor may also recommend a chest x-ray to check if the cancer has spread to the lung. To learn more about what to expect during common diagnostic tests, read Cancer.Net: Tests and Procedures. To learn about the terms used in this section, read the Cancer.Net Feature: Cancer Terms to Know: Newly Diagnosed. Staging
Staging is a way of describing a cancer, such as where it is located, if or where it has spread, and if it is affecting the functions of other organs in the body. Doctors use diagnostic tests to determine the cancer's stage, so staging may not be complete until all the tests are finished. Knowing the stage helps the doctor to decide what kind of treatment is best and can help predict a patient's prognosis (chance of recovery). There are different stage descriptions for different types of cancer. One tool that doctors use to describe the stage is the TNM system. This system uses three criteria to judge the stage of the cancer: the tumor itself, the lymph nodes around the tumor, and if the tumor has spread to other parts of the body. The results are combined to determine the stage of cancer for each person. The stage provides a common way of describing the cancer, so doctors can work together to plan the best treatments. There are four stages of intraocular melanoma: stages I through IV (one through four).
TNM is an abbreviation for tumor (T), node (N), and metastasis (M). Doctors look at these three factors to determine the stage of cancer:
Some ophthalmologists may not use the TNM system to stage an intraocular tumor. However, they still consider the size of the tumor and how it is affecting a person’s vision when deciding on a treatment plan. Specific information about the TNM system is listed below. In eye cancer, T for an iris melanoma is described differently than T for choroidal and ciliary body melanomas. N and M are described the same for iris, choroidal, and ciliary body melanomas. Tumor. Using the TNM system, the “T” plus a letter and/or number (0 to 4) is used to describe the size and location of the tumor. Some stages are also divided into smaller groups that help describe the tumor in even more detail. The following classifications are the same for any type of intraocular melanoma: TX: The primary tumor cannot be evaluated. T0: There is no tumor in the eye. Iris melanoma An iris tumor is classified as T1, T2, T3, and T4. T1: The tumor is limited to the iris. T1a: The tumor is in one quadrant (one-fourth) or less of the iris. T1b: The tumor is in more than one quadrant of the iris. T1c: The tumor is only in the iris, but there is melanomalytic glaucoma. This means that a buildup of certain cells in the eye blocks the flow of fluid in the eye, causing pressure. T2: The tumor has joined or grown into the ciliary body and/or choroid. T2a: The tumor has joined or grown into the ciliary body and/or choroid with melanomalytic glaucoma. T3: The tumor has joined or grown into the ciliary body and/or choroid and extends to the sclera (outer wall of the eyeball). T3a: The tumor has joined or grown into the ciliary body and/or choroid and extends to the sclera in association with melanomalytic glaucoma. T4: The tumor has spread to the outside of the eyeball, the optic nerve, or to the eye socket. This is called extraocular extension. Ciliary body and choroid melanoma A tumor in the ciliary body and choroid is also classified as T1, T2, T3, and T4 based on the size of the tumor. The doctor may measure the tumor size in units called optic disc diameters or millimeters (mm). The tumor is measured for width and height (also called thickness). T1: The tumor is 10 mm or smaller in diameter and 2.5 mm thick or smaller. T1a: The tumor is 10 mm or smaller and 2.5 mm thick or smaller and has not spread beyond the eyeball. T1b: The tumor is 10 mm or smaller and 2.5 mm thick or smaller, and there is microscopic spread beyond the eyeball. T1c: The tumor is 10 mm or smaller and 2.5 mm thick or smaller, and there is visible spread beyond the eyeball (called macroscopic spread). T2: The tumor is between 10 mm and 16 mm in its greatest diameter and between 2.5 mm and 10 mm thick. T2a: The tumor is between 10 mm and 16 mm in its greatest diameter and between 2.5 mm and 10 mm thick, and has not spread beyond the eyeball. T2b: The tumor is between 10 mm and 16 mm in its greatest diameter and between 2.5 mm and 10 mm thick, and there is some microscopic spread beyond the eyeball. T2c: The tumor is between 10 mm and 16 mm in its greatest diameter and between 2.5 mm and 10 mm thick, and there is some macroscopic spread beyond the eyeball. T3: The tumor is more than 16 mm in diameter and/or is more than 10 mm thick, but has not spread beyond the eyeball. T4: The tumor is more than 16 mm in diameter and more than 10 mm thick and has spread to the outside of the eyeball, the optic nerve, or the eye socket. This is called local extraocular extension. Node. The “N” in the TNM staging system stands for lymph nodes, the tiny, bean-shaped organs that help fight infection. Lymph nodes near the eye are called regional lymph nodes. Lymph nodes in other parts of the body are called distant lymph nodes. N is described the same for iris, ciliary body, and choroidal melanomas. NX: The regional lymph nodes cannot be assessed. N0 (N plus zero): There is no regional lymph node metastasis. N1: There is regional lymph node metastasis. Distant metastasis. The “M” in the TNM system indicates whether the cancer has spread from the eye to other parts of the body. M is described the same for iris, ciliary body, and choroidal melanomas. MX: Distant metastasis cannot be assessed. M0 (M plus zero): There is no distant metastasis. M1: There is metastasis to other parts of the body. Cancer stage grouping Doctors assign the stage of the cancer by combining the T, N, and M classifications. Stage I: The tumor diameter is 10 mm or smaller, the tumor’s thickness is 2.5 mm or smaller, and the tumor has not spread to the regional lymph nodes or other areas in the body (T1, T1a, T1b, or T1c; N0, M0). Stage II: The tumor is between 10 mm and 16 mm in diameter, is between 2.5 mm and 10 mm thick, and has not spread to the regional lymph nodes or other areas of the body (T2, T2a, or T2b; N0, M0). Stage III: The tumor is more than 16 mm in diameter and/or is more than 10 mm thick. It may or may not have spread beyond the eyeball, but has not spread to the regional lymph nodes or to other areas of the body (T3 or T4; N0, M0). Stage IV: The tumor has spread to either the regional lymph nodes and/or other areas of the body, regardless of how large the tumor is (any T, N1, M0; or any T, any N, M1). Recurrent: This is cancer that has come back after treatment. It may return in the eye or in another part of the body. Histopathology and grading After a biopsy or when the tumor is surgically removed, doctors may look at the types of cells that are in the tumor. This is called histopathology, and there are three types of histopathology patterns that may be present in the tumor:
Generally, a tumor made up of spindle cells has a better prognosis than a tumor made up of epithelioid cells. The tumor is given a grade to describe the composition of its cells. A lower grade generally indicates a better prognosis than a higher grade. GX: The grade cannot be assessed G1: A spindle cell melanoma G2: A mixed cell melanoma G3: An epithelioid melanoma Used with permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Sixth Edition (2002) published by Springer-Verlag New York, www.springer-ny.com. Treatment
The treatment of intraocular melanoma depends on the size and location of the tumor, whether the cancer has spread, and the patient’s overall health. The main goals in treating intraocular melanoma are to reduce the risk of the tumor spreading and to maintain the health and vision of the eye, if possible. In many cases, a team of doctors may work with the patient to determine the best treatment plan. This section outlines treatments that are the standard of care (the best treatments available) for this specific type of cancer. Patients are also encouraged to consider clinical trials as a treatment option when making treatment plan decisions. A clinical trial is a research study to test a new treatment to prove it is safe, effective, and possibly better than standard treatment. Your doctor can help you review all treatment options. For more information, visit the Clinical Trials section. Active surveillance/observation The doctor may recommend this approach if the intraocular melanoma is small or slow-growing and/or if treating the cancer would cause more discomfort than the disease itself, such as for people without any symptoms, older or seriously ill people, or people with a tumor in their only useful eye. The cancer is monitored closely, and treatment begins if the tumor shows signs of becoming more aggressive or spreading. This approach may also be called observation, watchful waiting, or watch-and-wait. If the tumor grows bigger than 10 mm in diameter or 2 mm to 3 mm in height (thickness), then the doctor and the patient may decide to proceed with treatment. Some people may be worried that the cancer should be treated right away. Because treating the cancer has side effects, some of which can be harmful to the eye, doctors may not want to treat a smaller tumor until it starts to demonstrate growth or has high-risk features. Surgery Surgery to the eye is quite common in the treatment of intraocular melanoma. During surgery, the ophthalmologist will remove parts of the affected eye, or even the entire eye, depending on the size and spread of the tumor.
In some cases, surgery may also be used to place a radioactive disc for internal radiation therapy (brachytherapy). More information about radiation therapy is below. The potential side effects of eye surgery are similar to that of any surgery, including a risk of infection, problems from the general anesthesia (the medication used during surgery), and pain. With total removal of the eye, there is a slight risk that the tumor could come back in the orbit. Many patients want to know immediately whether the surgery was successful. However, the success of an operation is hard to tell right away because it may take months before the doctors can determine if all of the cancer cells were removed during surgery. Having an eye removed Sometimes the only choice a doctor has in treating intraocular melanoma is to remove the eye. Because of this visual loss, a person with one eye may have trouble with depth perception. Most people adjust to these differences. Many people worry about what they will look like when they have an eye removed. The cosmetic surgery available today usually yields good cosmetic results. To fill the area left by the missing eye, the person is fitted for a prosthesis (artifical eye). The prothesis will look and behave almost the same as a natural eye. For example, the artifical eye will move along with the person’s remaining eye, just not as much as a natural eye moves. Family members may be able to tell that the eye is not real, but it is unlikely that strangers will know. If enucleation is required, talk with your doctor about a prosthesis; it may take many weeks for patients to receive the prosthesis. Radiation therapy Radiation therapy is the use of high-energy x-rays or other particles to kill cancer cells. The most common type of radiation treatment is called external-beam radiation therapy, which is radiation given from a machine outside the body. When radiation treatment is given using implants, it is called internal radiation therapy or brachytherapy.
Radiation therapy may result in a variety of side effects, so it is important to talk with your ophthalmologist about what to expect. The extent of side effects depends on the type and dose of radiation therapy the person receives, where the tumor is located, and the patient’s general health. The side effects may not show up right away.
The following side effects are less common and can cause a loss of vision:
If there is significant damage to the eye from radiation therapy, the eye may need to be removed. Laser therapy This procedure uses heat in the form of a laser to shrink a smaller tumor. It may also be called thermotherapy or transpupillary thermotherapy (TTT). This treatment potentially has fewer side effects than surgery or radiation therapy. Laser therapy may also be combined with radiation therapy. Treatment by disease and stage Iris melanoma Iris melanoma is not generally actively treated unless the tumor begins to grow, although there can be exceptions. The following are examples of common treatment options:
Small choroidal and ciliary body tumor The following are some treatment options for a small choroidal or ciliary body tumor:
Careful observation is a common treatment plan, although patients and their doctors may choose another option depending upon the location of the tumor or if the tumor begins to grow. Medium choroidal and ciliary body tumor The two most common treatment options for medium-sized choroidal and ciliary body melanoma are radiation therapy and enucleation. It is believed that there is no difference in survival rates between these two treatment methods for a medium-sized choroidal tumor. The following are treatment options for a medium-sized tumor:
In addition, the combination of laser therapy and radiation therapy (sometimes called “sandwich therapy”) is being used more frequently to treat this types of tumor. Large choroidal and ciliary body tumor For a large tumor, enucleation is the usual treatment. Results of the Collaborative Ocular Melanoma Study (COMS) revealed that patients had similar survival rates whether they received radiation therapy before enucleation or had their eye removed with no prior radiation treatment. Enrolling in a clinical trial may be another option for people with large choroidal and ciliary body tumors, as is additional radiation brachytherapy. Recurrent intraocular melanoma Recurrent melanoma is melanoma that has come back after previous treatment. Enucleation is one of the main treatments if a person’s eye has not yet been removed. A person with recurrent intraocular melanoma may also consider enrolling in a clinical trial. Extraocular extension melanoma If the tumor has spread to the outside of the eye, optic nerve, or eye socket, the doctor may recommend removal of the eye. Or, the doctor may perform a modified enucleation, which is the removal of the eyeball and adjacent structures. In some cases, the doctor may decide to remove the entire eye and the adjacent structures in a process called an exenteration. If the spread is small, some doctors will try to save the eye by removing the outer part of the tumor and treating the eye with radiation therapy. Talk with your doctor about possible treatment options. Metastatic intraocular melanoma This is melanoma that has spread from the eye to other parts of the body, such as the liver. Treatment options include treating the disease in the affected organ or enrolling in a clinical trial. Palliative treatment can also be used to reduce pain, control symptoms, and make a person more comfortable. To learn about the terms used in this section, read the Cancer.Net Feature: Cancer Terms to Know: During Treatment. Clinical Trials Resources
Doctors and scientists are always looking for better ways to treat patients with eye cancer. A clinical trial is a way to test a new treatment to prove that it is safe, effective, and possibly better than a standard treatment. Patients who participate in clinical trials are among the first to receive new treatments before they are widely available. However, there is no guarantee that the new treatment will be safe, effective, or better than a standard treatment. One clinical trial that has shaped how intraocular melanoma is treated is called COMS. Patients decide to participate in clinical trials for many reasons. For some patients, a clinical trial is the best treatment option available. Because standard treatments are not perfect, patients are often willing to face the added uncertainty of a clinical trial in the hope of a better result. Other patients volunteer for clinical trials because they know that finding new drugs and other therapies is the only way to make progress in treating eye cancer. Even if they do not benefit directly from the clinical trial, their participation may benefit future patients with eye cancer. To join a clinical trial, patients must complete a learning process known as informed consent. During informed consent, the doctor should list all of the patient’s options, so the person understands how the new treatment differs from the standard treatment. The doctor must also list all of the risks of the new treatment, which may or may not be different from the risks of standard treatment. Finally, the doctor must explain what will be required of each patient in order to participate in the clinical trial, including the number of doctor visits, tests, and the schedule of treatment. Learn more about clinical trials, including patient safety, phases of a clinical trial, deciding to participate in a clinical trial, questions to ask the research team, and links to find cancer clinical trials. Side Effects
Cancer and its treatment can cause a variety of side effects. However, doctors have made major strides in recent years in reducing pain, nausea and vomiting, and other physical side effects of cancer treatments. Many treatments used today are less intensive but as effective as treatments used in the past. Doctors also have many ways to provide relief to patients when such side effects do occur. Fear of treatment side effects is common after a diagnosis of cancer, but it may be helpful to know that preventing and controlling side effects is a major focus of your health-care team. Before treatment begins, talk with your doctor about possible side effects of the specific treatments you will be receiving. The specific side effects that can occur depend on a variety of factors, including the type of cancer, its location, the individual treatment plan (including the length and dosage of treatment), and the person’s overall health. Ask your doctor which side effects are most likely to happen (and which are not), when side effects are likely to occur, and how they will be addressed by the health-care team if they do happen. Also, be sure to communicate with the doctor about side effects you experience during and after treatment. For more information on the most common side effects of cancer and different treatments, along with ways to prevent or control them, visit Cancer.Net’s section on Managing Side Effects, based on ASCO’s curriculum. In addition to physical side effects, there may be psychosocial (emotional and social) effects as well. Learn more about the importance of addressing these needs in Cancer.Net’s section on Caring for the Whole Patient. For more information on late effects or long-term side effects, please read the After Treatment section or talk with your doctor. After Treatment
After treatment for eye cancer ends, talk with your doctor about developing a follow-up care plan. This plan may include regular physical examinations and/or medical tests to monitor your recovery in the coming months and years. The follow-up care plan for people with intraocular melanoma will depend on the treatment they received. People who have had radiation therapy or have had no treatment, but are being carefully observed, should have the tumor monitored closely, about every three to six months. Patients who have had the eye surgically removed should receive a yearly eye examination, and doctors should monitor the orbit closely for the next two to three years. All people treated for intraocular melanoma need to be monitored to watch for any sign that the cancer may have spread to other areas of the body. This process may include a physical examination, blood work, and imaging tests, such as chest x-rays, ultrasound tests, CT scans, or PET scans, every six to 12 months. Your doctor can work with you to decide on an appropriate follow-up care plan. People recovering from eye cancer are encouraged to follow established guidelines for good health, such as maintaining a healthy weight, not smoking, eating a balanced diet, and having recommended cancer screening tests. Talk with your doctor to develop a plan that is best for your needs. Moderate physical activity can help rebuild your strength and energy level. Your doctor can help you create an appropriate exercise plan based upon your needs, physical abilities, and fitness level. Learn more about Healthy Living After Cancer. To learn about the terms used in this section, read the Cancer.Net Feature: Cancer Terms to Know: After Treatment. Current Research
Research for eye cancer is ongoing. The following advances may still be under investigation in clinical trials and may not be approved or available at this time. Always discuss all diagnostic and treatment options with your doctor. Genetics/tumor biology. As with other types of cancer, researchers are studying the genes and proteins that may be involved in the development of intraocular melanoma. These studies may eventually lead to better treatment options. Researchers are also looking for markers, or specific substances in the blood, that may tell the doctor if the tumor has spread to other parts of the body. Researchers are also performing biopsies on the tumors to help predict whether a specific tumor is likely to spread to other parts of the body. Improving radiation therapy. Doctors are finding ways to make radiation therapy safer by reducing the side effects to the eye. These methods include adjusting the dose of radiation and finding better ways to direct radiation only at the tumor. Doctors are also experimenting with “sandwich therapy,” which is a combination of laser therapy and radiation disc therapy. Biologic therapy. Biologic therapy is also called immunotherapy, which is designed to boost the body’s natural defenses to fight cancer. It uses materials either made by the body or in a laboratory to bolster, target, or restore immune system function. Several types of biologic therapies are being tested in clinical trials in people with advanced intraocular melanoma.
Chemotherapy. Chemotherapy is the use of drugs to kill cancer cells. Systemic chemotherapy is delivered through the bloodstream, targeting cancer cells throughout the body. The side effects of chemotherapy depend on the individual and the dose used, but can include fatigue, risk of infection, nausea and vomiting, loss of appetite, and diarrhea. These side effects usually go away once treatment is finished. New types of chemotherapy are being tested in patients with advanced melanoma. Sometimes this is combined with new drugs that help shut off the blood supply to the tumor, called anti-angiogenesis drugs. The medications used to treat cancer are continually being evaluated. Talking with your doctor is often the best way to learn about the medications prescribed for you, their purpose, and their potential side effects or interactions with other medications. Learn more about your prescriptions through Cancer.Net's Drug Information Resources, which provides links to searchable drug databases. Treating liver metastases. Because intraocular melanoma commonly metastasizes to the liver, many people need treatment to the liver. A technique called chemoembolization allows doctors to separate the blood supply of the liver from the rest of the body and then deliver chemotherapy directly to the liver. Questions to Ask the Doctor
Regular communication with your doctor is important in making informed decisions about your health care. Consider asking the following questions of your doctor: General questions:
For patients who need surgery:
For patients who need an eye removed:
For patients who need radiation therapy:
After treatment:
Patient Information Resources
The Eye Cancer Network The Foundation of the American Academy of Ophthalmology National Eye Institute View all of Cancer.Net's Patient Information Resources. |
